Who Is a Better Candidate for Microneedling Than PRP
Which types of hair loss and which patients respond better to microneedling than to PRP?
Most people walk in wanting to know which treatment is better, and that's the wrong question. Microneedling wins in a fairly narrow, predictable band of cases, and outside that band the two sit close enough that your contraindications, your budget and your willingness to put something on your scalp every day end up deciding it. Working out which band you're in is most of what candidate selection actually means.
Microneedling outperforms platelet-rich plasma mainly in early to moderate pattern loss at Norwood II to IV or Ludwig I to II when it's paired with topical minoxidil, and in patients blocked from an autologous blood product by a platelet disorder, anticoagulation, active infection or pregnancy.
Which hair loss diagnoses respond to microneedling but see little benefit from platelet-rich plasma?
Your diagnosis, not your preference, is what separates these two most sharply, and only a handful of conditions genuinely tilt toward needling. Get the diagnosis wrong and you don't just waste money, you spend the window in which the right therapy could have saved what's still there. That's why trichoscopy, and a biopsy when the picture doesn't fit, comes before any device or syringe.
| Diagnosis | Microneedling | Platelet-rich plasma |
|---|---|---|
| Androgenetic alopecia | Strong, but only combined with a topical | Reasonable evidence, works alone |
| Early traction alopecia | Helpful once the tension is removed | Little comparative evidence |
| Telogen effluvium | Wrong mechanism, follicles are intact | Growth factor signal fits the problem |
| Alopecia areata | Avoid, wounding risks koebner spread | Studied as an alternative, some signal |
| Established cicatricial alopecia | Nothing left to stimulate | Nothing left to stimulate |
Needling combined with topical minoxidil has produced roughly four times the mean hair count increase of minoxidil alone over twelve weeks, while needling used on its own performs much closer to placebo.
How does the degree of follicular miniaturization affect which of the two treatments a patient is better served by?
Miniaturization is the most useful predictor on your scalp because it tells you how much biological material is left to work with. A healthy scalp carries most hairs above roughly fifty micrometres in shaft diameter in units of three or more; a miniaturizing one shows rising diameter diversity, a shift toward single-hair units and a growing crop of thin vellus-like hairs.
Hair diameter diversity above twenty per cent in men and above ten per cent in women marks a miniaturizing scalp, and a baseline global photograph plus a marked trichoscopy site repeated at three and six months converts the argument about whether anything is working into a hair count and a diameter figure.
Which medical conditions and medications rule a patient out of platelet-rich plasma while still allowing microneedling?
The exclusion list here is longer than most people expect, and the reason is structural: platelet-rich plasma is a blood product, so anything wrong with your blood is wrong with the therapy. Needling clears most of those hurdles because nothing gets drawn, concentrated or put back in.
- Platelet and clotting disorders: Thrombocytopenia, platelet dysfunction, hypofibrinogenaemia and haemodynamic instability are treated as absolute blocks.
- Active malignancy: Haematological cancer, metastatic disease and current chemotherapy exclude it on platelet quality and growth factor concerns.
- Anticoagulants and antiplatelets: Warfarin, direct oral anticoagulants and clopidogrel degrade activation; pausing them is the prescriber's call.
- Infection, pregnancy, breastfeeding: Systemic or local infection rules it out outright; pregnancy is excluded on absent safety data.
Thrombocytopenia, platelet dysfunction syndromes, hypofibrinogenaemia and critical haemodynamic instability are conventionally absolute contraindications to platelet-rich plasma, while microneedling stays available because nothing is drawn, concentrated or reinjected, though active scalp infection, current isotretinoin use, a keloid tendency and poorly controlled diabetes restrict it too.
How does scalp scarring or active inflammation change which treatment is appropriate?
Inflammation flips the usual logic of this comparison, because the very mechanism that makes needling work is what makes it dangerous here. Deliberately wounding a scalp with active disease can extend that disease into skin that was still holding, so a treatment meant to thicken your hairline ends up widening the loss. There's a sequence that keeps you out of that trap, and it isn't quick.
- Read the scalp before touching it: Perifollicular erythema, perifollicular scale, lost follicular ostia and tufting under trichoscopy stop a needling plan before it starts.
- Settle the scarring question: Non-scarring loss keeps visible follicular openings; scarring loss shows smooth shiny skin with the openings gone, and a punch biopsy reporting perifollicular lymphocytic infiltrate and fibrosis settles it when examination can't.
- Treat the disease first: Topical or intralesional corticosteroid, hydroxychloroquine or doxycycline, whichever the specific diagnosis calls for, comes before any procedural thought.
- Document quiescence: Something in the order of six to twelve months of quiet disease before a procedure is even discussed.
- Treat only surviving territory: Where fibrosis has replaced the follicular unit, nothing reaches anything, so both options are off for regrowth in that patch.
Micro-wounding a scalp with active lichen planopilaris, frontal fibrosing alopecia or discoid lupus can trigger the koebner response and drive new lesions along the line of injury, so needling stays off the table until the inflammation has been documented quiet for six to twelve months.
Why do budget and treatment-commitment realities push some candidates toward microneedling first?
Cost decides more of these cases than clinicians like to admit, and it decides them honestly, because a protocol you can't afford grows no hair. Both treatments need indefinite maintenance, since neither one changes the androgen sensitivity driving the loss, so gains slip away within months of stopping. That makes the real question at consultation not which treatment is biologically superior, but which one you'll still be doing in month nine.
| What it costs you | Platelet-rich plasma | Microneedling |
|---|---|---|
| Induction course | 3 to 4 sessions, 4 to 6 weeks apart | Monthly in clinic, or weekly at home |
| Per session | Several hundred to around a thousand dollars | Far lower, or the price of one clinic visit for a home device |
| Maintenance | Every 3 to 6 months, indefinitely | Same device, used for years |
| Home version | None | 0.5 to 1.0 mm roller or stamp pen |
| Time per session | 45 to 60 minutes plus a day or two of tenderness | About 10 minutes in your bathroom |
A platelet-rich plasma course of three to four induction sessions at several hundred to around a thousand dollars each, plus maintenance every three to six months, puts a realistic first year well into four figures with no insurance coverage, while a 0.5 to 1.0 millimetre home device costs about one clinic visit and lasts years.
What role does concurrent topical minoxidil use play in selecting microneedling over injections?
The delivery effect is the single strongest argument for choosing needling, and it's also the argument that collapses the moment you decide you won't use a topical. Channels opened at 0.5 to 1.5 millimetres bypass the stratum corneum for hours, and absorption studies across various actives show order-of-magnitude jumps through that window, which turns an ordinary minoxidil application into a much more potent one.
The twelve-week comparison of weekly needling plus five per cent minoxidil against minoxidil alone reported a mean hair count gain roughly four times larger in the combination arm, and that result is combinatorial, so needling on its own should never be sold as carrying it.
Which patients are poor candidates for both treatments and need a different pathway entirely?
A real share of the people who book a consultation for either treatment should be leaving with something else entirely. Some are too far along for any stimulatory therapy, some have a cause nobody has looked for yet, and some are being offered a procedure before the drugs with the best evidence have even been tried.
- Too far along: A Norwood VI to VII scalp or a Ludwig III crown needs transplant surgery, not stimulation.
- Unexamined systemic driver: Ferritin under thirty, thyroid disease, recent surgery, rapid weight loss, post-partum change.
- Proven drugs never tried: Finasteride, dutasteride, spironolactone or oral minoxidil address the mechanism these procedures only support.
- Wrong problem entirely: Trichotillomania, body dysmorphic disorder, or an expectation of an adolescent hairline back.
Iron deficiency with a ferritin below about thirty nanograms per millilitre, thyroid dysfunction, recent illness or surgery, rapid weight loss and post-partum change all produce shedding that resolves when the cause is corrected, which is why baseline bloods belong in the workup before any procedure is booked.
How do age and sex influence the response each treatment produces?
How long you've been losing hair predicts your response better than how old you are, but the two travel together often enough that age stays a useful shorthand. What age really sets is the expected size of the result, and that's worth hearing out loud at consultation, because an older patient quoted a younger patient's outcome will be disappointed by a perfectly normal response.
Dermal wound healing, collagen synthesis, platelet count and growth factor concentration all decline with age, so the concentrate drawn from a seventy year old is not the preparation it would have been at thirty, and female pattern loss spreads a mechanical treatment's effect over a wider diffuse area than a man's localized vertex or frontal recession.
What assessment steps at consultation determine which treatment a patient should start with?
A good consultation reaches the treatment decision almost as a by-product, because by the time the assessment is done the options have usually narrowed to one or two on their own. The practical questions about money, needles and daily topicals belong at the end, asked neutrally, not as a lead-in to a recommendation someone already made.
- History: When the loss started, gradual or sudden, patterned or diffuse, family history both sides, recent illness or surgery or childbirth, and what's already been tried.
- Trichoscopy and pull test: Document hair diameter diversity, single-hair unit proportion, follicular ostia, perifollicular erythema or scale, yellow and black dots, plus active shedding.
- Baseline bloods: Ferritin, full blood count including platelets, thyroid function and vitamin D, with androgen studies where a woman shows signs of hyperandrogenism.
- Biopsy when the picture doesn't fit: Reserved for suspected scarring, and worth the delay in the cases where it applies.
- Medication and bleeding history: A separate, deliberate screen covering anticoagulants, antiplatelets, regular anti-inflammatories, clotting disorders, malignancy and pregnancy.
- Standardised photography: Fixed distance, angle and lighting with a marked trichoscopy site, taken before anything is done, then reviewed at three and six months.
A baseline panel of ferritin, full blood count including platelets, thyroid function and vitamin D does double duty, because the same platelet count that screens for a systemic cause also determines whether a platelet concentrate is viable at all.
